Workflow
神经退行性疾病研究
icon
Search documents
段睿:蔡磊直播间全网经济体量第三, 支持科研外资金有盈余
Nan Fang Du Shi Bao· 2026-01-31 16:43
"做这件事,我先生真能被治愈吗?我不知道。"1月29日,在新京报2025年度公益致敬礼上,蔡磊妻 子、"蔡磊破冰驿站"创始人段睿称,她认为近几年蔡磊团队攻克渐冻症的工作,是一件不计当下回报的 事。她认为这已然是一项公益事业。 2019年,时任京东集团副总裁的蔡磊被确诊为肌萎缩侧索硬化症(ALS,俗称"渐冻症")。患病后蔡磊 开始组建团队攻克渐冻症,面对资金难题,"蔡磊破冰驿站"直播间成立,开始直播带货。 蔡磊在今年接受媒体采访时说,在过去两年,他本人及其团队科研总投入超过8000万元,其中大部分科 研资金来自直播所得。此外,蔡磊在今年初的公开信中还透露,上述投入中有对外科研捐款约6000万 元,六年来团队科研总投入已超一亿元。 段睿回忆,蔡磊确诊渐冻症时,他们陷入了迷茫与恐慌。这源于病症对身体的侵蚀,对家庭的重压,与 罕见病本身的诸多未知。彼时蔡磊已是京东集团副总裁,在并不普通的社会身份下,他希望能为更多的 病友做些什么。"我们能不能用十年攻克这个疾病,让未来不再有有这样的悲剧发生?" 然而"攻克渐冻症"起步并不容易,资金是一个大问题。段睿表示,她和蔡磊常说,以二人的积累,能在 很多领域创业,唯独动辄要投入上 ...
20年内患者数量将翻番,现每年经济负担近千亿元!帕金森病目前仍无特效药
Di Yi Cai Jing· 2026-01-26 10:23
郁金泰团队利用人工智能的蛋白结构预测和虚拟筛选技术,从7000余种药物中成功找到了一种针对帕金 森病的候选新药bemcentinib,并通过体外实验和动物实验证实小分子bemcentinib可有效抑制帕金森病的 关键靶点FAM171A2蛋白和病理性α-突触核蛋白结合,从而抑制多巴胺能神经元对该致病蛋白纤维的摄 取。 现有的传统药物和手术治疗都只针对帕金森病的症状进行治疗,不能延缓疾病进展,因而进一步研究帕 金森病的致病原理并开展针对性治疗,成为全球相关领域科学家竞相探索的战略高地。 1月26日,两院院士揭晓2025十大科技进展。其中,复旦大学研究院副院长、复旦大学附属华山医院神 经内科郁金泰团队在全球首次发现的帕金森病全新治疗靶点FAM171A2及基于该靶点的候选药物入选 2025中国十大科技进展。 帕金森病是仅次于阿尔茨海默病的第二常见的神经退行性疾病,严重影响患者日常生活,致残率和死亡 率较高。我国每年死于帕金森病的人数超过7万人。 现有的传统药物和手术治疗都只针对帕金森病的症状进行治疗,不能延缓疾病进展,因而进一步研究帕 金森病的致病原理并开展针对性治疗,成为全球相关领域科学家竞相探索的战略高地。 郁金 ...
最新发表国际合作论文合集:揭示衰老和神经退行性疾病生物标志物
Huan Qiu Wang Zi Xun· 2025-07-16 05:59
Core Insights - The global neurodegenerative disease proteomics alliance (GNPC) has revealed biomarkers related to aging and neurodegenerative diseases, providing new insights into the biology of major neurodegenerative diseases like Alzheimer's and Parkinson's [1][2] - The research published in the journals Nature Medicine and Nature Aging highlights unique protein biomarkers that could lead to early detection and improved outcomes for neurodegenerative diseases [1][3] Group 1: Research Findings - The GNPC's flagship paper analyzed one of the world's largest proteomic datasets, comprising approximately 250 million unique protein measurements from 35,000 biological fluid samples, including plasma and cerebrospinal fluid [2] - The study identified specific proteins associated with Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis [2][3] - The research established disease-specific plasma biomarker profiles and identified common protein features among Alzheimer's, Parkinson's, and frontotemporal dementia [3] Group 2: Implications for Diagnosis and Treatment - The authors identified a cerebrospinal fluid and plasma protein feature associated with the APOEε4 allele, known to increase Alzheimer's disease risk, suggesting broader implications for other neurodegenerative diseases [3] - The study also revealed age-related changes in cognition-related proteins, providing new insights into how protein level changes in cerebrospinal fluid and plasma relate to cognitive health [3] - The importance of international collaboration, data sharing, and diverse datasets is emphasized for accelerating discoveries in neurodegenerative research, with future studies aimed at developing new diagnostic, preventive, and therapeutic approaches [3]